Akademik Veri Yönetim Sistemi
Turk Hijyen ve Deneysel Biyoloji Dergisi, cilt.71, sa.1, ss.1-8, 2014 (Scopus)
Objective: Infections of Pseudomonas aeruginosa and Acinetobacter baumannii are one of the greatest concerns for hospitalized patients, particularly those in intensive care units (ICUs). The aim of this study was to determine the antimicrobial resistance percentages and to assess empirical treatment options for bloodstream infections due to P. aeruginosa and A. baumannii strains in ICU patients. Methods: Resistance percentages of strains isolated in January-December 2010 and January-December 2011 were separately analyzed and compared. The differences in resistance percentages between two intervals was statistically analyzed. Results: A statistically significant decrease was found in the resistance percentage of piperacillin-tazobactam, cefoperazone-sulbactam, ceftazidime, ciprofloxacin, gentamicin, amikacin and netilmicin in the second period compared with the first (p values were 0.0059, 0.0000, 0.0048, 0.00350, 0.0000, 0.0000, 0.0003, respectively) for P. aeruginosa strains. Whereas resistance percentage of aztreonam was increased (p value was 0.0155). Resistance percentage of imipenem was found similar. In A.baumannii strains, a statistically significant decrease was found in resistance percentage of cefepime and amikacin in the second period compared with the first (p values were 0.0003, 0.0000). Resistance percentage of ampicillin-sulbactam, piperacillin-tazobactam and imipenem was increased (p values were 0.0003, 0.0210, 0.0033). There was no colistin resistance determined in both species. Tigecycline resistance was not found in A. baumannii isolates. Conclusion: Active surveillance of antibiotic resistance percentages of isolated strains especially in ICUs serves to determine empirical treatment regimens in every institution. The present study emphasized that antibiotic usage policy is an important step to combat hospital infections. Consequently, infection control measures should be taken, empirical treatment regimens should be constantly reviewed, and should be determined according to active surveillance data in order to decrease resistance percentages.